AT1-receptor blocker-based combination therapy in hypertension.

Abstract

Despite an increase in the number of patients treated for hypertension, blood pressure control is achieved in a minority of patients. The use of rational, well-tolerated combination regimens with complementary modes of action, such as an AT1-receptor blocker administered with a low dose of a thiazide diuretic, provides an effective and well-tolerated management strategy for patients who require more than monotherapy to control blood pressure. In clinical trials in patients with mild-to-moderate hypertension, a newly available combination of candesartan cilexetil-hydrochlorothiazide (HCT) 16/12.5 mg was significantly more effective than either monotherapy. This combination was also more effective than losartan-HCT 50/12.5 mg in two double-blind, randomized studies in patients with mild, moderate or severe hypertension. Furthermore, the antihypertensive efficacy of candesartan cilexetil-HCT was evident at up to 48 h following the last dose, while the effect of losartan-HCT declined rapidly during this period. Thus, the new fixed-dose AT1-receptor blocker/diuretic combination, candesartan cilexetil-HCT 16/12.5 mg combines enhanced efficacy with excellent tolerability and sets a new standard for the treatment of hypertension requiring more than monotherapy.

• Authors: P Trenkwalder
• Journal: Blood pressure. Supplement (Blood Press Suppl) Issue 3 Pg. 18-25 ( 2001) ISSN: 0803-8023 [Print] Sweden
• PMID: 11683473 (Publication Type: Journal Article, Review)

Chemical References

• Angiotensin Receptor Antagonists
• Antihypertensive Agents
• Benzothiadiazines
• Diuretics
• Receptor, Angiotensin, Type 1
• Sodium Chloride Symporter Inhibitors

Topics

• Angiotensin Receptor Antagonists
• Antihypertensive Agents (administration & dosage, adverse effects, therapeutic use)
• Benzothiadiazines
• Diuretics
• Drug Interactions
• Drug Therapy, Combination
• Humans
• Hypertension (drug therapy)
• Receptor, Angiotensin, Type 1
• Sodium Chloride Symporter Inhibitors (administration & dosage, adverse effects, therapeutic use)